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Background
Hereditary Angioedema (HAE) is a rare disease charac-
terized by recurrent angioedema attacks involving lar-
ynx, abdomen, extremities and various body parts. The
reactions are by and large self-limited, but potentially,
could be fatal. Until recently, the only approved treat-
ment in Canada is an intravenous C1-esterase inhibitor
infusion. However, intravenous therapy can be challen-
ging for those who have co-morbid disorders. Icatibant
(Firazyr®) —which received approval in Canada in June
2014 — offers administration through subcutaneous
delivery. Through a special access program, here we pre-
sent self-administered icatibant treatment on a female
subject with Charcot-Marie-Tooth disease, a rare
genetic, neuromuscular disorder, which limits her ability
to self-administer intravenous therapy.
Methods
During each icatibant self-administration event, a diary
method was used to collect the following patient-
reported outcomes: attack intensity, anatomical location
& trigger, number of doses, onset of relief, time elapsed
until complete resolution, and adverse reactions.
Results
From 2012- May 2014, the patient logged a total of 12
events, in which she treated each attack with a single
self-administered 30 mg dose of icatibant via subcuta-
neous injection. She experienced moderate to severe
abdominal and peripheral HAE attacks. Onset of relief
occurred within 15 – 30 minutes and complete resolu-
tion occurred within 4-hours to 5-days. Adverse reac-
tions were mild in severity, transient, and resolved
without further intervention. They included local injec-
tion site reaction (100%), headache (58%), fatigue (25%),
feeling “fuzzy-brained” (25%), and hot flush (8%).
Conclusion
This case report provides supporting evidence for icatibant
as an effective, safe and viable subcutaneous therapeutic
alternative to intravenous treatments for patients with
HAE.
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